

Eurofins Medinet Strengthens US Leadership Team With the Appointment of Kevin Smith, BS, MBA, Director of Central Laboratory Operations, Eurofins Medinet Washington DC

December 1, 2008 - Washington, DC

Eurofins Medinet is pleased to announce the addition of Kevin Smith, BS, MBA as Director of Central Laboratory Operations on December 1, 2008. Mr. Smith will lead the central laboratory operations at the Eurofins Medinet laboratory in Washington DC, reporting directly to Rene van Erp, Managing Director of Eurofins Medinet worldwide. Mr. Smith brings over 8 years of experience working in laboratories and clinical research facilities. Most recently as the CRO Manager – Outsourcing for Novartis Pharma in Basel, Switzerland, Mr. Smith was responsible for global vendor selection, contract negotiation and finalization. He also maintained internal metrics and made sure that that processes and procedures were adhered to for project budgets and schedules.

Mr. Smith has also worked in Princeton, New Jersey for CentraLabs Clinical Research, where he was Head of Project and Data Management. He was strongly involved in the integration of business systems, especially globally, creating a network of allied business partners. This also included global data management responsibilities and integration of a global dataset.

Kevin received his Bachelor of Science (Honors) in Biological Sciences – Immunology from Nescot, Surrey, UK. He also received his MBA from Reading University, UK. He has a great deal of international business experience in the clinical research/life sciences fields.

For more information about Eurofins Medinet, please visit us online at www.eurofinsmedinet.com or contact:

Eurofins Medinet Washington DC
Tel: +1 703 480-2500
Fax: +1 703 480-2654
Email: info@eurofinsmedinet.com

Notes for the editor:

About Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with

high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach.

Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

About Eurofins Medinet

Eurofins Medinet provides a full range of global central laboratory testing services including safety parameters, biomarker development and analysis, and specialized testing in bioanalysis, pharmacokinetics, microbiology and genomics using its fully standardized and accredited central laboratories in the Netherlands, USA (two laboratories), France, Singapore and China.

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.